Medpace (NASDAQ:MEDP) Releases Quarterly Earnings Results, Beats Estimates By $0.71 EPS

Medpace (NASDAQ:MEDP - Get Free Report) issued its quarterly earnings data on Monday. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $2.96 by $0.71, Zacks reports. Medpace had a return on equity of 50.87% and a net margin of 17.66%. Medpace updated its FY 2025 guidance to 11.930-12.690 EPS.

Medpace Price Performance

Shares of Medpace stock traded up $5.94 during trading hours on Thursday, reaching $342.41. The company had a trading volume of 419,377 shares, compared to its average volume of 270,103. The firm has a market cap of $10.64 billion, a PE ratio of 29.98, a price-to-earnings-growth ratio of 1.85 and a beta of 1.36. Medpace has a one year low of $302.01 and a one year high of $459.77. The business has a fifty day simple moving average of $343.70 and a 200 day simple moving average of $348.88.

Analyst Ratings Changes

A number of analysts recently commented on MEDP shares. Robert W. Baird increased their price target on Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Baird R W downgraded Medpace from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 23rd. TD Cowen reduced their price objective on Medpace from $413.00 to $372.00 and set a "buy" rating for the company in a report on Wednesday, October 23rd. Finally, William Blair reissued an "outperform" rating on shares of Medpace in a report on Tuesday, October 22nd. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.